VRVinod Raina

Vinod Raina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vinod Raina has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial

    by Atul Sharma, Bidhu Kalyan Mohanti, Surendra Pal Chaudhary, V. Sreenivas, Ranjit Kumar Sahoo, Nootan Kumar Shukla, Sanjay Thulkar, Sujoy Pal, Surya V. Deo, Sushmita Pathy, et al.


  • Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a Phase II randomized study

    by Soumyajit Roy, Sushmita Pathy, Bidhu Kalyan Mohanti, Vinod Raina, Anand Jaiswal, Rakesh Kumar, Mani Kalaivani

    Objective:To evaluate the feasibility and efficacy of accelerated hypofractionated radiation with concomitant chemotherapy (AHFx-RT-CT) in locally advanced squamous cell carcinoma (SCC) of lung.Methods:Thirty-six patients were enrolled in this study (CTRI/2013/11/004143). Patients in arm A (n=18) received neoadjuvant chemotherapy(NACT) (paclitaxel 200mg/m2 and carboplatin AUC 5) followed by external radiotherapy (60Gy/30fractions/6weeks). Arm B (n=18) received NACT as in arm A followed by AHFx-RT (48Gy/20fractions/4weeks) with concomitant chemotherapy (cisplatin 30mg/m2 weekly). Primary end points included comparative evaluation of overall loco-regional response rates (ORR), progression free survival (PFS). Secondary endpoints included toxicity, quality of life (QOL) and overall survival (OS).Results:Median follow-up duration was 15 months. The ORR at first follow-up (72.2% vs. 44%, p=0.06) and at 1 year after treatment completion (61% vs. 5.5%, p=0.04) were superior in arm B. The median PFS (17 months vs...


  • Final results of a phase III randomized controlled trial comparing modified gemcitabine + oxaliplatin (mGEMOX) to gemcitabine+ cisplatin in management of unresectable gall bladder cancer (GBC).

    by Atul Sharma, Nootan Kumar Shukla, Surendra Pal Chaudhary, Ranjit Sahoo, Bk Mohanti, S. V. S. Deo, Sujoy Pal, Sanjay Thulkar, Sunil Kumar, Sushmita Pathy, et al.

    4077 Background: Combination of gemcitabine and platinum (cisplatin/ oxalipatin) though standard for advanced/unresectable GBC has not been directly compared. This study was designed to see if OS with mGEMOX is equivalent to GemCis. Methods: Single center phase III randomized trial. Primary end point was OS in 2 groups. Main Secondary end points were: 1. PFS in 2 groups; 2. RR in two groups. Considering median OS of 9.5 month in mGEMOX (as per our previous study) and 11.7month in GemCis 108 patients were required in each arm to have γ ±2 month with 80% power. To account for protocol violation and lost to follow up additional 22 patients in each arm were enrolled. Treatment protocol: Arm A- mGEMOX Oxaliplatin 80 mg/m2 and Gemcitabine 900 mg/m2 day1 and 8 maximums of 6 cycles, Arm B- GemCis Cisplatin 25 mg/m2 Gemcitabine 1000 mg/m2 day1 and 8 maximums of 8 cycles, repeated every 3 weeks. Results: Between February 2010 and July 2015, 260 patients with unresectable/metastatic GBC subjects were randomly assigned in a 1:1 ratio to mGEMOX or GemCis. 243 patients (119 in mGEMOX and 124 in GemCis) received at least 1 dose of chemotherapy and were considered analyzable. Subjects in 2 groups were well matched for baseline characteristics. Median number of cycles was 4 in both the groups. 33.4% in mGEMOX and 25.8% in GemCis completed the assigned treatment. Median follow up of surviving patients is 10.5 months (range 4.5-47). Median OS in mGEMOX is 9 months (95% CI = 7.77-10.22) and 8 months in GemCis arm (95% CI = 7.40-8.59); p = 0.152. Median PFS in mGEMOX is 6 months (95% CI = 4.72-7.27) and 4.5 months in GemCis arm (95% CI = 3.44-5.55); p = 0.123. 29.4% (35) and 18.5% (23) patients survived 12 month or longer in mGEMOX and GemCis arms respectively (p = 0.442). 23.5% and 22.6% subjects achieved objective CR/PR in mGEMOX and GemCis arms respectively. Toxicity was comparable except more grade 3/4 diarrhea, and grade 1/2 peripheral neuropathy in mGEMOX arm. Conclusions: This study confirms that 6 cycles of mGEMOX is equivalent to 8 cycles of GemCis and one of these may be chosen for initial treatment. Clinical trial information: CTRI/2010/091/001406.


  • Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung

    by Soumyajit Roy, Sushmita Pathy, Rakesh Kumar, Bidhu K. Mohanti, Vinod Raina, Anand Jaiswal, Sameer Taywade, Kavita Garg, Sanjay Thulkar, Anant Mohan, et al.

    The study assessed the role of 18F-fluorodeoxyglucose (18F-FDG) Positron emission tomography (PET)/computed tomography (CT) in evaluating the prognostic value of metabolic response for progression-free survival (PFS) and overall survival (OS) in patients with locally advanced non-small-cell lung cancer (NSCLC). Thirty patients with locally advanced NSCLC were enrolled in this prospective study and randomly allocated to one of two treatment arms. Arm A (n=15) received two cycles of neoadjuvant chemotherapy [paclitaxel (200 mg/m2) and carboplatin (AUC5)] and external beam radiotherapy (60 Gy/30 fractions/6 weeks). Arm B (n=15) received the same neoadjuvant chemotherapy followed by external beam radiotherapy (48 Gy/20 fractions/4 weeks) with concomitant cisplatin 30 mg/m2 weekly. Patients underwent 18F-FDG PET/CT at baseline and after 6 weeks of completion of intended treatment. Pretreatment and post-treatment maximum standardized uptake values (SUVmax) were noted. Patients with a reduction of SUVmax more than 50% were considered to be metabolic responders and those with a reduction 50% or less as nonresponders. Median follow-up was 18.98 months. Twenty-one patients completed the intended treatment. The median pretreatment and post-treatment SUVmax values were 14 and 6.4 for arm A and 15.3 and 3.5 for arm B, respectively. Significant decrease in SUVmax was observed in both arms. Metabolic response in arm A and arm B was 50 and 64%, respectively. The median PFS and OS of the responders were 22.31 and 24.73 months and those for nonresponders were 7.83 and 8.26 months, respectively. No significant difference in OS and PFS was observed between responders and nonresponders in the two arms. PET/CT distinguishes responders from nonresponders early after completion of chemoradiation in patients with locally advanced NSCLC, but did not provide any prognostic significance.


  • Open Access

    Circulating cell-free DNA and its integrity as a prognostic marker for breast cancer

    by Sobuhi Iqbal, Sreenivas Vishnubhatla, Vinod Raina, Surabhi Sharma, Ajay Gogia, Suryanarayana S V Deo, Sandeep Mathur, Nutan Kumar Shukla

    The aim of our study was to look for alternative predictive biomarkers for breast cancer management in limited resource setup. A comprehensive analysis of circulating cell-free DNA (CCFD) in serum at baseline was performed to assess its prognostic potential. Quantitative polymerase chain reaction (qPCR) of ALU sequences using ALU115 and ALU247 primers was carried out in patients (N: baseline 148, postoperative 47) and 51 healthy controls. Mean serum DNA integrity, levels of ALU 247 and levels of ALU 115 were significantly higher in patients than in healthy females. No significant differences were observed in the levels ALU 247 and ALU 115 between stage IV and earlier stages of the disease. The DNA integrity was significantly higher in stage IV than earlier stages. A significant decrease in DNA integrity was observed after surgery (pre: 0.55 ± 0.23 vs post: 0.43 ± 0.30; P = 0.002) while no such change could be observed for ALU 247 and ALU 115. Baseline DNA integrity was significantly higher in relapsed patients than in patients who were free of disease (P = 0.005). Higher baseline DNA integrity was also indicated, though statistically not significant, in patients who died (P = 0.14). In contrast, ALU 247 and ALU 115 levels were decreased in died patients as compared to survivors (24.8 ± 34.80 vs 73.5 ± 170.83, P = 0.02 for ALU 247 and 41.0 ± 47.99 vs 159.5 ± 299.54, P = 0.005 for ALU 115). Baseline levels of ALU 115 and ALU 247 were lower in relapsed patients, though statistically not significant. In univariate analysis, the only clinic-pathological parameter associated with disease prognosis was tumor size. The hazards of 5-year overall mortality was 3.60 (95 % CI: 1.03 12.53, P = 0.03) among patients with lower baseline serum levels of CCFD (ALU 247 < 21 and ALU 115 < 41). Similarly the 4 year hazards for recurrence was 2.30 (95 % CI: 0.96 5.52, P = 0.05) among patients with higher DNA integrity. Baseline serum levels of CCFD and its integrity were found to be potential prognostic biomarkers in patients of primary breast cancer at our centre.


  • Open Access

    Lung cancer: Prevalent trends & emerging concepts

    by Vinod Raina, Prabhat Singh Malik

    Indian J Med Res, Official publication of Indian Council of Medical Research,India


  • Quantitative assessment ofBAXtranscript and flow cytometric expression in acute myeloid leukemia: A prospective study

    by Surender Kumar Sharawat, Vinod Raina, Lalit Kumar, Atul Sharma, Radhika Bakhshi, Sreenivas Vishnubhatla, Ritu Gupta, Sameer Bakhshi

    Quantitative assessment of BAX transcripts and protein in acute myeloid leukemia (AML). We quantitatively evaluated BAX gene transcripts by real-time polymerase chain reaction (TaqMan probe chemistry) and protein expression by flow cytometry. Consecutive 112 AML patients with a median age of 16 (1-59) years were recruited in the study. By flow cytometry, the percentage expression was in linear correlation with relative median fluorescent intensity (RMFI; R = 0.4425; P < 0.001). However, there was no linear relationship between the transcript copies of the BAX with its RMFI (R = -0.0559; P = 0.586). The expression of the BAX at both protein and transcript level was significantly higher in AML patients as compared with normal control. RMFI of the BAX were higher in the cohort with lower white blood cell count (P = 0.029). None of the other baseline characteristics correlated with either the BAX transcript or the RMFI. BAX expression did not correlate with complete remission rate, event free, disease free, and overall survival. BAX gene expression in AML was evaluated first time with two different methods but did not correlate with the survival outcome.


  • Open Access

    Spontaneous tumor lysis syndrome in a patient of chronic lymphocytic leukemia

    by Ajay Gogia, Vinod Raina, Nida Iqbal, Vijaya Murugan

    Indian J Med Paediatr Oncol, Official publication of Indian Society of Medical and Paediatric Oncology


  • Open Access

    Non-Hodgkins lymphoma with lactic acidosis at presentation: A case report of a rare oncologic emergency

    by Arvind Kumar, Vinod Raina

    Lactic acidosis (LA) has been reported to be associated with high grade lymphoma as a terminal event. Its causes are multi-factorial. It can either occur due to overproduction of lactic acid by rapidly dividing tumor or due to its underutilization due to involvement of liver by lymphomatous deposits. The prognosis of lymphoma associated with LA is dismal. We present a patient of non-Hodgkins lymphoma (NHL) who presented with LA, after an initial response succumbed.